Proteome Sciences (LON:PRM) Trading Up 21.4% – Still a Buy?

Proteome Sciences plc (LON:PRM) shares traded up 21.4% during mid-day trading on Tuesday . The stock traded as high as GBX 2.50 and last traded at GBX 1.70. 1,530,633 shares traded hands during trading, an increase of 264% from the average session volume of 420,739 shares. The stock had previously closed at GBX 1.40.

Proteome Sciences Stock Down 19.0%

The company has a debt-to-equity ratio of -165.46, a current ratio of 0.13 and a quick ratio of 0.37. The stock has a market capitalization of £5.96 million, a PE ratio of -1.63 and a beta of 0.07. The company has a 50 day moving average price of GBX 1.58 and a 200-day moving average price of GBX 1.96.

Proteome Sciences (LON:PRM) last issued its quarterly earnings results on Wednesday, April 15th. The company reported GBX (1.04) earnings per share for the quarter. The firm had revenue of GBX 376 million during the quarter. Proteome Sciences had a positive return on equity of 33.80% and a negative net margin of 81.50%.

About Proteome Sciences

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.